Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
This study found that a permissive hypoxaemic oxygen saturation target of ≥ 90% for infants with acute viral bronchiolitis was as safe and clinically effective as a standard normoxic oxygen saturation target of ≥ 94%, with the lower oxygen saturation target dominating the economic analysis.
Abstract
Background:
There are no randomised trials of peripheral capillary oxygen saturation (SpO2) targets in acute respiratory infection. Two national guidelines recommended different targets for the management of acute viral bronchiolitis.
Objectives:
To compare the American Academy of Pediatrics guideline target of SpO2 ≥ 90% with the Scottish Intercollegiate Guidelines Network target of SpO2 ≥ 94%.
Design:
A multicentre, parallel-group, double-blind, randomised controlled, equivalence trial with economic evaluation.
Setting:
Eight paediatric hospital departments in the UK.
Participants:
Infants > 6 weeks and ≤ 12 months of age (corrected for prematurity) with physician-diagnosed bronchiolitis admitted to hospital from a paediatric emergency assessment area. Follow-up for 6 months by standardised telephone contacts.
Intervention:
Infants were randomised to a target oxygen saturation of ≥ 94% (standard care) or ≥ 90% (modified care) displayed by a pulse saturation oximeter (Masimo Corporation Limited, CA, USA).
Routine care:
All infants received routine care in addition to the study intervention. Infants were eligible for discharge when they exhibited a SpO2 of ≥ 94% in room air for 4 hours including a period of sleep and were also feeding adequately (≥ 75% usual volume).
Primary outcome:
A total of 615 infants were recruited, of whom 308 were allocated to the standard care group and 307 to the modified care group. The primary outcome was time to cough resolution. There was equivalence at the prespecified variance of ± 2 days [time to cough resolution: standard care group, 15 days; modified care group, 15 days; median difference 1 day (benefit modified), 95% confidence interval (CI) –1 to 2 days].
Secondary results:
Return to adequate feeding occurred sooner in infants in the modified care group than in those in the standard care group (19.5 vs. 24.1 hours). This difference was non-equivalent [median difference 2.7 hours (95% CI –0.3 to 7.0 hours) versus prespecified ± 4 hours; post-hoc hazard ratio 1.22 (95% CI 1.04 to 1.44 (p-value = 0.015)]. Parent perspective of the time taken to return to normal was not equivalent, being 12 days in the standard care group compared with 11 days in the modified care group [median difference 1.0 day (95% CI 0.0 to 3.0 days) versus prespecified ± 2 days; post-hoc hazard ratio 1.19 (95% CI 1.00 to 1.41); p-value = 0.043]. At 28 days, SpO2 was equivalent [mean difference 0.11% (95% CI –0.35% to 0.57%), within the 1% prespecified]. The modified care group (55.6%) required oxygen less than the standard care group (73.1%), and for a shorter period (5.7 hours vs. 27.6 hours). Infants in the modified care group were fit for discharge (30.2 hours vs. 44.2 hours, hazard ratio 1.46, 95% CI 1.23 to 1.73; p-value < 0.001) and were discharged (40.9 hours vs. 50.9 hours; hazard ratio 1.28, 95% CI 1.06 to 1.50; p-value < 0.003) sooner than those in the standard care group. There were 35 serious adverse events in the standard care group, compared with 25 in the modified care group. Eight infants in the standard care group and 12 in the modified care group were admitted to a high-dependency unit. By 28 days, 23 infants had been readmitted to hospital in the standard care group and 12 infants in the modified care group. Parents of infants in the modified care group did not experience higher levels of anxiety and, by 14 days, had lost 28% fewer hours to usual activities. NHS costs were £290 lower in the modified care group than in the standard care group, with additional societal costs also being lower in the modified care group.
Conclusions:
Management of infants to a SpO2 target of ≥ 90% is as clinically effective as ≥ 94%, gives rise to no additional safety concerns, and appears to be cost-effective. Future work could focus on the safety and effectiveness of using intermittent oxygen saturation monitoring in secondary care, and to consider what are safe and effective oxygen saturation targets for children with bronchiolitis managed in primary care.
Trial registration:
This trial is registered as ISRCTN28405428.
Funding:
This project was funded by the NIHR Health Technology Assessment programme. Masimo Corporation Limited, CA, USA, kindly provided oxygen saturation monitors with standard and altered algorithms.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Introduction
- Normoxaemia and hypoxaemia
- Clinical approach to hypoxaemia in respiratory disease
- Clinical response to supplemental oxygen in those with hypoxaemia
- Hypoxaemia in acute viral bronchiolitis
- Controversies in approach to hypoxaemia in bronchiolitis
- Potential health-care impact of clinical response to hypoxaemia in bronchiolitis
- Study aims
- Chapter 2. Methods
- Chapter 3. Results
- Chapter 4. Economic evaluation
- Chapter 5. Discussion
- Chapter 6. Conclusions
- Acknowledgements
- References
- Appendix 1a Bronchiolitis of Infancy Discharge Study Parent/Carer Consent Form Version 2.0, 16 May 2011
- Appendix 1b Bronchiolitis of Infancy Discharge Study Parent/Carer Consent Form Version 3.0, 30 May 2012
- Appendix 1c Bronchiolitis of Infancy Discharge Study Parent Information Sheet Version 2.0, 16 May 2011
- Appendix 1d Bronchiolitis of Infancy Discharge Study Parent Information Sheet Version 3.0, 30 May 2012, Scottish sites
- Appendix 1e Bronchiolitis of Infancy Discharge Study Parent Information Sheet Version 3.0, 30 May 2012, English sites
- Appendix 2 Summary of protocol amendments
- Appendix 3a Admission case report form version 1
- Appendix 3b Admission case report form version 2
- Appendix 3c Pertussis notification case report form
- Appendix 3d Discharge case report form version 1
- Appendix 3e Discharge case report form version 2
- Appendix 3f Discharge case report form version 4: Scottish sites
- Appendix 3g Discharge case report form version 4: English sites
- Appendix 3h 7-day follow-up case report form
- Appendix 3i 14-day follow-up case report form
- Appendix 3j 28-day follow-up case report form version 1
- Appendix 3k 28-day follow-up case report form version 2
- Appendix 3l 6-month follow-up case report form version 1
- Appendix 3m 6-month follow-up case report form version 4
- Appendix 4 Trial Steering Committee: terms of reference and membership
- Appendix 5 Data Monitoring Committee
- Appendix 6 Trial management
- List of abbreviations
Article history
The research reported in this issue of the journal was funded by the HTA programme as project number 09/91/16. The contractual start date was in July 2011. The draft report began editorial review in June 2014 and was accepted for publication in November 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
Dr Steve Cunningham has the following potential competing interests: (1) current chair of the National Institute for Health and Care Excellence Bronchiolitis Guideline Group; (2) past chair of the Scottish Intercollegiate Guideline Network Bronchiolitis Guideline Group; (3) principal investigator for Alios Pharmaceuticals Phase 1 investigational medicine for treatment of infants with bronchiolitis; and (4) consultancy work on behalf of NHS Lothian for Ablynx Pharmaceuticals Phase 1 product development for treatment of infants with bronchiolitis.
- NLM CatalogRelated NLM Catalog Entries
- Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial.[Lancet. 2015]Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial.Cunningham S, Rodriguez A, Adams T, Boyd KA, Butcher I, Enderby B, MacLean M, McCormick J, Paton JY, Wee F, et al. Lancet. 2015 Sep 12; 386(9998):1041-8.
- Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review.[Health Technol Assess. 2015]Saline in acute bronchiolitis RCT and economic evaluation: hypertonic saline in acute bronchiolitis - randomised controlled trial and systematic review.Everard ML, Hind D, Ugonna K, Freeman J, Bradburn M, Dixon S, Maguire C, Cantrill H, Alexander J, Lenney W, et al. Health Technol Assess. 2015 Aug; 19(66):1-130.
- Intermittent vs Continuous Pulse Oximetry in Hospitalized Infants With Stabilized Bronchiolitis: A Randomized Clinical Trial.[JAMA Pediatr. 2021]Intermittent vs Continuous Pulse Oximetry in Hospitalized Infants With Stabilized Bronchiolitis: A Randomized Clinical Trial.Mahant S, Wahi G, Bayliss A, Giglia L, Kanani R, Pound CM, Sakran M, Kozlowski N, Breen-Reid K, Arafeh D, et al. JAMA Pediatr. 2021 May 1; 175(5):466-474.
- Review WITHDRAWN: Glucocorticoids for acute viral bronchiolitis in infants and young children.[Cochrane Database Syst Rev. 2008]Review WITHDRAWN: Glucocorticoids for acute viral bronchiolitis in infants and young children.Patel H, Platt R, Lozano JM. Cochrane Database Syst Rev. 2008 Jan 23; (1):CD004878. Epub 2008 Jan 23.
- Review Glucocorticoids for acute viral bronchiolitis in infants and young children.[Cochrane Database Syst Rev. 2004]Review Glucocorticoids for acute viral bronchiolitis in infants and young children.Patel H, Platt R, Lozano JM, Wang EE. Cochrane Database Syst Rev. 2004; (3):CD004878.
- Bronchiolitis of Infancy Discharge Study (BIDS): a multicentre, parallel-group, ...Bronchiolitis of Infancy Discharge Study (BIDS): a multicentre, parallel-group, double-blind, randomised controlled, equivalence trial with economic evaluation
- Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT...Online remote behavioural intervention for tics in 9- to 17-year-olds: the ORBIT RCT with embedded process and economic evaluation
- Interventions designed to improve therapeutic communications between black and m...Interventions designed to improve therapeutic communications between black and minority ethnic people and professionals working in psychiatric services: a systematic review of the evidence for their effectiveness
- The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligatio...The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation
- Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis...Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation
Your browsing activity is empty.
Activity recording is turned off.
See more...